A double blinded randomized controlled cross-over trial to evaluate the efficacy of NOQ19 an anti-inflammatory Ayurvedic medicine for Adult Chronic Inflammatory Lung Diseases

Kartikey Exploration Mining Services Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年10月16日

试验速览

暂无简介。

•Screened participants with ‘Yes’ answer to all the following questions will be eligible to take part in the study:
•1)Those having chronic inflammatory lung disease identified (CILD)as follows - mild, moderate and severe symptoms(not lung function tests) as shown in the below asthma severity table since a month; patients notified by the pulmonologist or physicians to the study staff as CILD; cough more than four weeks and history of use of bronchodilators presumed to have CILD.
•2)People willing to give their consent to participate in the study
•3)People residing in and around Chandrapur
•4)Male or non-pregnant female adult =18 years of age at time of enrollment
•5) No contraindications to NOQ19 – Ayurvedic Proprietary Medicine/any herbal medicine, such as allergy or have history of severe gastritis or peptic ulcer.

•Screened patients with ‘Yes’ answer to any of the following questions will not be eligible to participate in the study:
•1)Patients of CILD with co-morbidities such as heart diseases, renal disease, hepatic diseases, cancer, autoimmune diseases or neurological diseases or other infectious disease like Tuberculosis etc.
•2) Lactating mothers and pregnant women
•3)Patients on other therapies (homeopathic, Siddha, Ayurveda or any other prescribed Ayurveda drug) along with the trial drug and not willing for the trial herbal drug
•4)Treating physician considers the patient unfit to administer the intervention
•5)History of recent severe gastritis, peptic ulcer or hematemesis
•6)Enrolled in another trial

发起方

Kartikey Exploration Mining Services Pvt Ltd